This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pankuch, G. A.
Right arrow Articles by Appelbaum, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pankuch, G. A.
Right arrow Articles by Appelbaum, P. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2002, p. 42-46, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.42-46.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Antipneumococcal Activity of Ertapenem (MK-0826) Compared to Those of Other Agents

Glenn A. Pankuch,1 Todd A. Davies,1 Michael R. Jacobs,2 and Peter C. Appelbaum1*

Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033,1 Department of Pathology, Case Western Reserve University, Cleveland, Ohio 441062

Received 8 March 2001/ Returned for modification 25 August 2001/ Accepted 25 September 2001

The activities of ertapenem (MK-0826) and eight other agents against a range of penicillin-susceptible and -resistant pneumococci were tested by determination of MICs by the microdilution method and by the time-kill methodology. For 125 penicillin-susceptible, 74 penicillin-intermediate, and 86 penicillin-resistant pneumococci, the MICs at which 50% of isolates are inhibited (MIC50s) and MIC90s, as determined by the microdilution method, were as follows: for ertapenem, 0.016 and 0.03, 0.125 and 0.5, and 0.5 and 1.0 µg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for amoxicillin, <=0.016 and 0.03, 0.25 and 1.0, and 2.0 and 2.0 µg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for cefprozil, 0.125 and 0.25, 1.0 and 8.0, and 16.0 and 16.0 µg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for cefepime, <=0.016 and 0.06, 0.5 and 1.0, and 1.0 and 2.0 µg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for ceftriaxone, <=0.016 and 0.06, 0.25 and 1.0, and 1.0 and 2.0 µg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for imipenem, <=0.008 and <=0.008, 0.03 and 0.25, and 0.25 and 0.25 µg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for meropenem, <=0.008 and 0.016, 0.125 and 0.5, and 0.5 and 1.0 µg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; and for clarithromycin, 1.0 and >32.0, 1.0 and >32.0, and >32.0 and >32.0 µg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively. For 64 strains for which quinolone MICs were increased (ciprofloxacin MICs, >=4.0 µg/ml), the MIC90 of ertapenem was 1.0 µg/ml and the MIC90s of the other ß-lactams tested and clarithromycin were >32.0 µg/ml. Against four penicillin-susceptible, four penicillin-intermediate, and four penicillin-resistant strains, testing by the time-kill methodology showed that ertapenem at two times the MIC was bacteriostatic (99% killing) after 12 h and bactericidal (99.9% killing) against all strains by 24 h, with 90% killing of all strains at two times the MIC after 6 h. At the MIC, ertapenem was bacteriostatic against all strains tested after 24 h. Although the bactericidal activity of imipenem at the MIC after 24 h was significantly greater than that of ertapenem, the kinetics of the two drugs at two times the MIC were similar after 24 h. The killing kinetics of clarithromycin were slower than those of ertapenem and other agents, with clarithromycin at two times the MIC having bactericidal activity against seven of eight macrolide-susceptible strains after 24 h.

* Corresponding author. Mailing address: Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail: pappelbaum{at}psu.edu.

Antimicrobial Agents and Chemotherapy, January 2002, p. 42-46, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.42-46.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Burkhardt, O., Majcher-Peszynska, J., Borner, K., Mundkowski, R., Drewelow, B., Derendorf, H., Welte, T. (2005). Penetration of Ertapenem Into Different Pulmonary Compartments of Patients Undergoing Lung Surgery. J Clin Pharmacol 45: 659-665 [Abstract] [Full Text]  
  • Kosowska, K., Hoellman, D. B., Lin, G., Clark, C., Credito, K., McGhee, P., Dewasse, B., Bozdogan, B., Shapiro, S., Appelbaum, P. C. (2005). Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin. Antimicrob. Agents Chemother. 49: 1932-1942 [Abstract] [Full Text]  
  • Marchese, A., Gualco, L., Schito, A. M., Debbia, E. A., Schito, G. C. (2004). In vitro activity of ertapenem against selected respiratory pathogens. J Antimicrob Chemother 54: 944-951 [Abstract] [Full Text]  
  • Jones, R. N., Huynh, H. K., Biedenbach, D. J., Fritsche, T. R., Sader, H. S. (2004). Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 54: 144-154 [Abstract] [Full Text]  
  • Livermore, D. M., Sefton, A. M., Scott, G. M. (2003). Properties and potential of ertapenem. J Antimicrob Chemother 52: 331-344 [Abstract] [Full Text]  
  • Cottagnoud, P., Pfister, M., Cottagnoud, M., Acosta, F., Tauber, M. G. (2003). Activities of Ertapenem, a New Long-Acting Carbapenem, against Penicillin-Sensitive or -Resistant Pneumococci in Experimental Meningitis. Antimicrob. Agents Chemother. 47: 1943-1947 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»